Session Title: Quick Fire Free Paper Session 03
Session Date/Time: Sunday 29/09/2013 | 08:30-09:30
Paper Time: 09:25
Venue: Hall C (Level 1)
First Author: B.Wu CHINA
Co Author(s): B. Wu R. Gao C. Yao X. Lin
To evaluate the therapeutic effect of Lucentis on choroidal neovascularization (CNV).
Guangzhou Aier Ophthalmic Hospital in China
Methods A definite diagnosis of CNV was made in 8 cases by fundus fluorescein angiography ( FFA), indocyanine green angiography ( ICGA) and optic coherence tomography (OCT). CNV was treated 3 times with Lucentis by cavum vitreum injection at a dose of 0.5 mg (0.05 m1) once a month．Clinical data were collected before treatment, 1 and 3 months after treatment. Therapeutic effects of Lucentis on CNV were observed.
The acuity of vision improved in 3 ( 37.5％) out of the 8 cases 1 month after treatment，and improved in 4 ( 50％) out of the 8 cases 3 months after treatment. The intraocular pressures (IOP) 1 and 3 months after treatment were both normal. There was no significant difference between IOP before treatment and IOP after treatment. FFA and ICGA showed that the exudates were decreased or resolved at different extent. Average thickness of central macular retina detected by OCT was (611.0±259.6)μm before treatment, and （248.9±109.9)μm ,（231.3±48.8)μm respectively 1 and 3 months after treatment. Compared with average thickness of central macular retina before treatment, it decreased significantly after 1 or 3 months treatment. Retinal edema and serous detachment were significantly improved after treatment. No obvious adverse effects were found.
Injection of Lucentis into vitreous cavity is a safe and effective treatment for CNV.